Literature DB >> 3288754

Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use.

S L Wallace1, J Z Singer.   

Abstract

Published experiences with severe toxicity with intravenous colchicine have been reviewed. All reported cases reflect inappropriate use of the drug. Therapeutic rules for colchicine have been derived from this information: (1) Single intravenous doses should not exceed 2-3 mg, and cumulative total doses for an attack should not be more than 4-5 mg. (2) Patients should receive no more colchicine by any route for 7 days. (3) Colchicine doses must be reduced in the presence of renal or hepatic disease, and in the older patient with apparently normal renal function. (4) Intravenous colchicine doses should be half the size of oral ones. (5) Absolute contraindications to intravenous colchicine therapy for acute gout include combined renal and hepatic disease, creatinine clearances below 10 cc/min, and extrahepatic biliary obstruction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288754

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

Review 1.  Colchicine--expanding horizons.

Authors:  A Schattner
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 2.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

3.  Safety and efficacy of intravenous Colchicine in children with Familial Mediterranean Fever.

Authors:  Rotem Tal; Rotem Semo Oz; Gil Amarilyo; Tal Eidlitz-Marcus; Ori Goldberg; Yoel Levinsky; Orit Peled; Liora Harel
Journal:  Rheumatol Int       Date:  2019-06-22       Impact factor: 2.631

4.  Colchicine sensitizes human hepatocellular carcinoma cells to damages caused by radiation.

Authors:  Chia-Yuan Liu; Hui-Fen Liao; Shou-Chuan Shih; Shee-Chan Lin; Wen-Hsiung Chang; Cheng-Hsin Chu; Tsang-En Wang; Yu-Jen Chen
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

5.  Reversal of colchicine-induced mitotic arrest in Chinese hamster cells with a colchicine-specific monoclonal antibody.

Authors:  S K Rouan; I G Otterness; A C Cunningham; H E Holden; C T Rhodes
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

6.  Acute and chronic toxicities of colchicine in Brachydanio rerio.

Authors:  H Roche; G Bogé; G Pérès
Journal:  Bull Environ Contam Toxicol       Date:  1994-01       Impact factor: 2.151

Review 7.  Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

Authors:  S Schlee; L C Bollheimer; T Bertsch; C C Sieber; P Härle
Journal:  Z Gerontol Geriatr       Date:  2017-02-28       Impact factor: 1.281

Review 8.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Prevention and management of gout.

Authors:  V L Star; M C Hochberg
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 10.  Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field.

Authors:  Robert L Wortmann
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.